MRI Safe Neurostimulation Systems Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

MRI Safe Neurostimulation Systems Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

MRI Safe Neurostimulation Systems Market Size

MRI Safe Neurostimulation Systems Market size will register significant growth between 2024 and 2032 due to increasing approvals and permissions from governmental organizations. As regulatory bodies recognize the safety and efficacy of these systems in MRI environments, healthcare providers are more inclined to adopt them for patients requiring neurostimulation therapy. 
 

For instance, in January 2024, Abbott's Proclaim dorsal root ganglion (DRG) neurostimulator system received expanded MRI labeling approval from the US FDA for patients with complex regional pain syndrome (CRPS) affecting their lower limbs. This updated labeling permitted patients to undergo full-body MRI scans even while the device was implanted. According to Timothy Deer, MD, president and CEO of the Spine and Nerve Centers of the Virginias, this advancement ensures timely access to necessary care without the need to seek out specialized MRI facilities.
 

With the assurance of compatibility with MRI scans, these systems offer patients greater flexibility and access to advanced treatment options. Consequently, the market witnesses a surge in demand driven by the endorsement from regulatory authorities.
 

MRI safe neurostimulation systems market experiences escalating demand as more companies secure regulatory permissions for product usage. With an increasing number of neurostimulation systems receiving approval for compatibility with magnetic resonance imaging (MRI), healthcare providers gain confidence in adopting these technologies for patient care. As regulatory authorities endorse a growing array of neurostimulation systems for MRI scans, the market witnesses heightened interest from both healthcare professionals and patients seeking innovative solutions for pain management and neurological disorders. 
 

For instance, in February 2024, Mainstay Medical Holdings plc disclosed that they received a full-body MRI conditional labeling for the ReActiv8 Restorative Neurostimulation system from the US FDA. This approval is extended to all existing and prospective ReActiv8 patients in the United States utilizing the current 45 cm commercially available leads. It enabled ReActiv8 recipients to undergo 1.5T full-body MRI scans. 
 

MRI safe neurostimulation systems market faces constraints despite its growth trajectory. One significant challenge is the complexity and cost associated with ensuring compatibility with magnetic resonance imaging (MRI) machines, leading to higher device prices. Additionally, regulatory approval processes for MRI safe neurostimulation systems can be stringent and time-consuming, delaying market entry. Moreover, concerns regarding the long-term safety and efficacy of these systems in MRI environments may deter healthcare providers from widespread adoption. These factors collectively contribute to restraints hindering market expansion.
 

MRI Safe Neurostimulation Systems Market Trends

MRI safe neurostimulation systems industry experiences notable trends driven by advancements in pain management utilizing these devices. As research and development efforts continue to enhance the effectiveness and precision of neurostimulation systems, healthcare providers increasingly rely on them to address various chronic pain conditions. With growing recognition of their potential in alleviating neuropathic pain and improving patients' quality of life, the market witnesses a surge in demand. These advancements underscore the pivotal role of MRI-safe neurostimulation systems in shaping the future of pain management practices.
 

To cite an instance, in January 2022, Abbott announced that it received approval for its Proclaim systems enhanced magnetic resonance imaging (MRI) compatibility from the FDA. The expanded approval included MRI compatibility for the Proclaim XR spinal cord stimulation system, removing restrictions on lead tip location and radiofrequency power usage during MRI scans. The Proclaim XR neurostimulation system, approved by the FDA in September 2019, offered a combination of low-energy therapy and a low-dosing protocol to alleviate chronic pain while extending battery life.
 

MRI Safe Neurostimulation Systems Market Analysis

Based on application, the market size from the deep brain stimulation segment is estimated to collate strong progression by 2032. Deep brain stimulation (DBS) procedures are largely performed for the treatment of Parkinson’s disease. These procedures can help improve symptoms of stiffness, tremors, slowness, and movement problems. A rise in the geriatric population and the growing burden of Alzheimer’s disease, chronic migraine & pain, and autism will lead to market development.
 

As per the product, MRI-safe neurostimulation systems market from the implantable segment will expand exponentially, given the growing system penetration in healthcare facilities. The higher incidence of neurological disorders could elevate system adoption. Implantable systems are increasingly preferred over transcutaneous neurostimulation to offer reliable treatment results and the extended life of the device. However, higher investments and limited manufacturers of implantable neurostimulators in developing and under-developed countries will restrict industry progress.
 

North America is likely to emerge as a profitable avenue for MRI safe neurostimulation systems market. The rapidly expanding geriatric population and increasing prevalence of Alzheimer’s disease in the region could play an ideal role in the market expansion. Growing cases of neurostimulation implants and changing consumer lifestyles will add to the regional market outlook. Besides, advancements in technology and favorable reimbursement policies further fuel market gains. As healthcare facilities prioritize patient-centered care and seek innovative solutions for pain management, the demand for MRI-safe neurostimulation systems continues to rise steadily throughout North America.
 

MRI Safe Neurostimulation Systems Market Share

Major companies operating in MRI-safe neurostimulation systems industry competitive landscape include

• Medtronic
• Cyberonics
• Codman & Shurtleff’s
• Boston Scientific
• Biotronik
•  Neuronetics
•  Nevro Corp.
•  St. Jude Medical
• Sorin
• AADCO Medical.
   

MRI Safe Neurostimulation Systems Industry News

In August 2023, Medtronic introduced its latest innovation in the spinal cord stimulator domain, aiming to alleviate discomfort by automatically adjusting to users' movements. The Inceptiv device, designed as a closed-loop system, eliminated the need for constant user intervention to adjust neurostimulation therapy. With CE mark approval, the device was planned for launch in the European Union, offering users the advantage of undergoing MRI scans safely. Medtronic emphasized that it is the sole spinal cord stimulation system in Europe, providing full-body 1.5T and 3T MRI access, a crucial feature considering the likelihood of users needing an MRI within five years of implantation.

What Information does this report contain?